Comparative transcriptomic analysis of whole blood mycobacterial growth assays and tuberculosis patients' blood RNA profiles.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
21 10 2022
Historique:
received: 24 06 2022
accepted: 13 09 2022
entrez: 22 10 2022
pubmed: 23 10 2022
medline: 26 10 2022
Statut: epublish

Résumé

In vitro whole blood infection models are used for elucidating the immune response to Mycobacterium tuberculosis (Mtb). They exhibit commonalities but also differences, to the in vivo blood transcriptional response during natural human Mtb disease. Here, we present a description of concordant and discordant components of the immune response in blood, quantified through transcriptional profiling in an in vitro whole blood infection model compared to whole blood from patients with tuberculosis disease. We identified concordantly and discordantly expressed gene modules and performed in silico cell deconvolution. A high degree of concordance of gene expression between both adult and paediatric in vivo-in vitro tuberculosis infection was identified. Concordance in paediatric in vivo vs in vitro comparison is largely characterised by immune suppression, while in adults the comparison is marked by concordant immune activation, particularly that of inflammation, chemokine, and interferon signalling. Discordance between in vitro and in vivo increases over time and is driven by T-cell regulation and monocyte-related gene expression, likely due to apoptotic depletion of monocytes and increasing relative fraction of longer-lived cell types, such as T and B cells. Our approach facilitates a more informed use of the whole blood in vitro model, while also accounting for its limitations.

Identifiants

pubmed: 36271270
doi: 10.1038/s41598-022-20409-y
pii: 10.1038/s41598-022-20409-y
pmc: PMC9587058
doi:

Substances chimiques

RNA 63231-63-0
Interferons 9008-11-1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

17684

Subventions

Organisme : MRF
ID : MRF_MRF-160-0008-ELP-KAFO-C0801
Pays : United Kingdom
Organisme : Medical Research Council
ID : 1816898
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206508/Z/17/Z
Pays : United Kingdom

Informations de copyright

© 2022. The Author(s).

Références

PLoS One. 2017 Nov 15;12(11):e0185973
pubmed: 29140996
Prim Care. 2013 Sep;40(3):743-56
pubmed: 23958367
Front Pediatr. 2019 Apr 30;7:151
pubmed: 31114771
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Tuberculosis (Edinb). 2021 Mar;127:102033
pubmed: 33524936
Front Genet. 2018 Oct 04;9:457
pubmed: 30337941
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Acta Trop. 2013 Aug;127(2):75-81
pubmed: 23571106
Infect Immun. 2001 Jul;69(7):4195-201
pubmed: 11401954
BMJ Open. 2019 May 22;9(5):e026612
pubmed: 31122978
Bioinformatics. 2005 Aug 15;21(16):3439-40
pubmed: 16082012
Infect Immun. 2004 Nov;72(11):6401-7
pubmed: 15501770
Nat Biotechnol. 2019 Jul;37(7):773-782
pubmed: 31061481
J Immunol. 2018 Apr 15;200(8):3008-3019
pubmed: 29540577
J Vis Exp. 2011 Sep 14;(55):
pubmed: 21946922
PLoS Med. 2016 Oct 25;13(10):e1002152
pubmed: 27780211
PLoS Med. 2013 Oct;10(10):e1001538
pubmed: 24167453
Front Pediatr. 2019 Aug 27;7:350
pubmed: 31508399
Front Immunol. 2021 Mar 02;12:637164
pubmed: 33763081
Immunology. 2018 Feb;153(2):171-178
pubmed: 28921535
J Leukoc Biol. 2013 Oct;94(4):595-601
pubmed: 23625199
Tuberculosis (Edinb). 2015 Sep;95(5):527-31
pubmed: 26198113
N Engl J Med. 2014 May 01;370(18):1712-1723
pubmed: 24785206
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Adv Sci (Weinh). 2020 Feb 11;7(7):1902880
pubmed: 32274301
Lancet Infect Dis. 2021 Mar;21(3):366-375
pubmed: 33508221
Front Immunol. 2017 Apr 25;8:448
pubmed: 28487695
Lancet Respir Med. 2016 Mar;4(3):213-24
pubmed: 26907218
Sci Rep. 2018 Jan 12;8(1):661
pubmed: 29330469
Cytokine. 2012 Oct;60(1):30-3
pubmed: 22688013
Sci Rep. 2017 Sep 21;7(1):12094
pubmed: 28935874
Curr Opin Infect Dis. 2012 Jun;25(3):250-7
pubmed: 22491144

Auteurs

Petra Bachanová (P)

Department of Infectious Disease, Imperial College London, London, UK.

Ashleigh Cheyne (A)

Department of Infectious Disease, Imperial College London, London, UK.
MRC Centre for Molecular Bacteriology and Infection, Department of Life Sciences, Imperial College London, London, UK.

Claire Broderick (C)

Department of Infectious Disease, Imperial College London, London, UK.

Sandra M Newton (SM)

Department of Infectious Disease, Imperial College London, London, UK.
Centre for Paediatrics and Child Health, Imperial College London, London, UK.

Michael Levin (M)

Department of Infectious Disease, Imperial College London, London, UK.
Centre for Paediatrics and Child Health, Imperial College London, London, UK.

Myrsini Kaforou (M)

Department of Infectious Disease, Imperial College London, London, UK. m.kaforou@imperial.ac.uk.
Centre for Paediatrics and Child Health, Imperial College London, London, UK. m.kaforou@imperial.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH